Headlines about iCo Therapeutics (OTCMKTS:ICOTF) have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than 6,000 news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. iCo Therapeutics earned a daily sentiment score of 1.18 on their scale. InfoTrie also gave media coverage about the biotechnology company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock’s share price in the immediate future.

Shares of OTCMKTS ICOTF opened at $0.04 on Friday. iCo Therapeutics has a 1-year low of $0.03 and a 1-year high of $0.13. The business has a 50-day moving average of $0.04.

iCo Therapeutics Company Profile

iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.

Featured Story: What does it mean to hold a stock in street name?



Receive News & Ratings for iCo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iCo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link